Finance

Lists
Q3 2026 earnings • released • EPS miss -53.77% • Revenue beat +0.50%
See results
FME:ETR
Fresenius Medical Care AG
€42.23
-0.21%
(-0.090) 1D
Nov 6, 5:36:28 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for FME...
Open
€42.59
High
€42.60
Low
€41.50
Mkt. cap
11.36B
Avg. vol.
988.42K
Volume
1.26M
Dividend
3.53%
Quarterly dividend
€0.37
Ex-dividend date
May 22, 2026
P/E ratio
14.11
52-wk high
€45.90
52-wk low
€34.57
EPS
€2.99
Shares outstanding
268.56M
No. of employees
106K
Open
€42.59
High
€42.60
Low
€41.50
Mkt. cap
11.36B
Avg. vol.
988.42K
Volume
1.26M
Dividend
3.53%
Quarterly dividend
€0.37
Ex-dividend date
May 22, 2026
P/E ratio
14.11
52-wk high
€45.90
52-wk low
€34.57
EPS
€2.99
Shares outstanding
268.56M
No. of employees
106K
News stories
From web sources and news partners
Profile
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives. With a global headquarters in Bad Homburg vor der Höhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan. The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group's revenue. As of 2024, the company was ranked as #612 on the World's Best Employers list published by Forbes. Wikipedia
About Fresenius Medical Care AG
CEOHelen Giza
Employees106K
Founded1996
Headquarters-
SectorHealth Care
IndustryHealth care provider
Last report
Nov 3, 2026
Fiscal period
Q3 2026
€0.56 / €1.20
-53.77%miss
Revenue / Est. (EUR)
4.94B / 4.91B
+0.50%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
5.07B
4.61B
4.86B
4.94B
Cost of goods sold
3.68B
3.43B
3.55B
3.66B
Cost of revenue
3.68B
3.43B
3.55B
3.66B
Research and development expenses
38.63M
38.31M
39.63M
41.40M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
784.62M
748.94M
736.01M
743.60M
Operating expense
796.34M
803.94M
786.35M
799.91M
Total operating expenses
4.48B
4.24B
4.34B
4.46B
Operating income
592.03M
375.56M
523.63M
475.46M
Other non operating income
-
-
-
-
EBT including unusual items
508.46M
207.52M
383.00M
302.63M
EBT excluding unusual items
541.79M
334.44M
399.22M
405.36M
Income tax expense
106.44M
42.75M
89.83M
77.84M
Effective tax rate
20.93%
20.60%
23.45%
25.72%
Other operating expenses
-26.91M
16.69M
10.71M
14.91M
Net income
327.08M
117.53M
218.38M
159.78M
Net profit margin
6.45%
2.55%
4.49%
3.24%
Earnings per share
1.44
0.91
0.56
0.56
Interest and investment income
13.62M
14.62M
14.70M
16.05M
Interest expense
-99.02M
-93.30M
-97.55M
-97.50M
Net interest expenses
-85.40M
-78.68M
-82.86M
-81.46M
Depreciation and amortization charges
-
-
-
-
EBITDA
780.17M
727.79M
879.38M
829.79M
Gain or loss from assets sale
17.92M
8.77M
-4.09M
-7.18M
Upcoming events
AI content may include mistakes. Learn more
Google apps